BioNano Genomics Inc

BNGO10 Dec 2024
Healthcare
$0.24
+0.11 (+10.61%)
Lowest Today
$0.24
Highest Today
$0.27
Today’s Open
$0.24
Prev. Close
$0.23
52 Week High
$2.27
52 Week Low
$0.2
To Invest in BioNano Genomics Inc

BioNano Genomics Inc

Healthcare
BNGO10 Dec 2024
+0.11 (+10.61%)
1M
3M
6M
1Y
5Y
Low
$0.24
Day’s Range
High
$0.27
0.24
52 Week Low
$0.2
52-Week Range
52 Week High
$2.27
0.2
1 Day
-
1 Week
+10.67%
1 month return
-7.39%
3 month return
-41.03%
6 month return
-69.52%
1 Year return
-81.69%
3 Years return
-99.24%
5 Years return
-97.46%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
2.15
Vanguard Total Stock Mkt Idx Inv
1.34
Geode Capital Management, LLC
0.87
BlackRock Inc
0.6
GMT Capital Corp
0.52
Vanguard Institutional Extnd Mkt Idx Tr
0.5
Fidelity Extended Market Index
0.48

Market Status

Fundamentals
Market Cap
23.84 mln
PB Ratio
0.49
PE Ratio
0
Enterprise Value
23.33 mln
Total Assets
214.4 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Organisation
BioNano Genomics Inc
Employees
344
Industry
Medical Instruments & Supplies
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step